triptorelin (Decapeptyl® SR)

Reference No. 1658

Publication date:

14/03/2017

Appraisal information

triptorelin (Decapeptyl® SR) 22.5 mg powder and solvent for suspension for injection
triptorelin (Decapeptyl® SR) 11.25 mg powder for suspension for injection
triptorelin (Decapeptyl® SR) 3 mg powder for suspension for injection

Company:	Ipsen Ltd
BNF category:	Malignant disease and immunosupression
NMG meeting date:	11/01/2017
AWMSG meeting date:	15/02/2017

Submission Type:	Limited Submission
Status:	Recommended
Advice No:	0417
Ministerial ratification:	14/03/2017

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ministerial
Ratification

AWMSG advice

Triptorelin (Decapeptyl® SR) is recommended as an option for use within NHS Wales as an adjuvant treatment to radiotherapy in patients with high risk localised or locally advanced prostate cancer and as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.

Final Appraisal Recommendation (FAR)

Download

triptorelin (Decapeptyl SR) 1658 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

triptorelin (Decapeptyl SR) 1658 ASAR

Clinical Expert (CE) Summary

Download

triptorelin (Decapeptyl SR) 1658 CE summary